Harry Renco, MD
Internal Medicine · Prospect, KYNPI 1124093075
Payments from drug & device makers
Across 299 payments — averaging $16.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$774
- AbbVie$613
- Amgen$480
- GSK$390
- Takeda Pharmaceuticals U.S.A., Inc.$293
- Novartis$247
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,898100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 54 | $774 |
| AbbVie(2 entities) | 31 | $613 |
| Amgen | 31 | $480 |
| GSK | 27 | $390 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $293 |
| Novartis | 16 | $247 |
| Pfizer | 12 | $211 |
| AstraZeneca(2 entities) | 14 | $192 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $188 |
| Esperion Therapeutics, Inc. | 10 | $161 |
| Phathom Pharmaceuticals, Inc. | 8 | $159 |
| Vanda Pharmaceuticals Inc. | 8 | $154 |
| Lilly USA, LLC | 10 | $145 |
| Boehringer Ingelheim | 7 | $96 |
| Johnson & Johnson | 6 | $96 |
| Sanofi Pasteur Inc. | 5 | $92 |
| Sanofi-aventis U.S. LLC | 6 | $82 |
| Medtronic(2 entities) | 3 | $66 |
| Eisai Inc. | 4 | $65 |
| Axsome Therapeutics, Inc. | 3 | $63 |
| Endo Pharmaceuticals Inc. | 3 | $45 |
| Antares Pharma, Inc. | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Genentech USA, Inc. | 2 | $29 |
| Abbott | 2 | $27 |
| Qiagen, LLC | 1 | $24 |
| Seqirus USA Inc | 1 | $21 |
| Averitas Pharma Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Merck | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
How this compares
$4,898 in reported general payments places this provider in the 85th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 107 | $78,519 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $35,617 |
| XareltoRivaroxaban | 39 | $33,069 |
| FarxigaDapagliflozin Propanediol | 16 | $24,311 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $15,571 |
| MounjaroTirzepatide | 13 | $13,383 |
| JanuviaSitagliptin Phosphate | 20 | $11,027 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $10,199 |
| Testosterone | 12 | $10,100 |
| MyrbetriqMirabegron | 14 | $9,491 |
| NexletolBempedoic Acid | 14 | $6,143 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $5,379 |
| PaxlovidNirmatrelvir/Ritonavir | 12 | $2,858 |
| Valsartan | 82 | $2,797 |
| Ezetimibe | 70 | $2,434 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $211 | $81,377119 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $390 | $61,388108 claims |
| Johnson & JohnsonXarelto | $96 | $33,06939 claims |
| AstraZenecaFarxiga | $192 | $24,31116 claims |
| Lilly USA, LLCMounjaro | $145 | $13,38313 claims |
| MerckJanuvia | $17 | $11,02720 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $9,49114 claims |
| Esperion Therapeutics, Inc.Nexletol | $161 | $6,14314 claims |
| AbbVieSynthroid | $613 | $1,26414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Prospect
- Tina YuanProspect$15K
- Mark AdamsLondon$15.4M
- Matthew WenkerErlanger$12.8M
- Jason ChesneyLouisville$6.3M
- Neil FarrisLexington$3M
- David JohnsonOwensboro$787K
- Hollis ClarkMurray$780K
- Fares KhaterWhitesburg$412K
- Christopher PhillipsPaducah$315K
- Cynthia Bowman-StroudPaducah$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.